1.
Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiologica...
by Yusuf, Salim, Prof
The Lancet (British edition), 2011, Vol.378 (9798), p.1231-1243
2.
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Ang...
by Dahlöf, Björn
The Lancet (British edition), 2005, Vol.366 (9489), p.895-906
3.
Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent...
by Muntner, Paul
Hypertension (Dallas, Tex. 1979), 2014, Vol.64 (5), p.1012-1021
4.
Prevalence of Resistant Hypertension in the United States, 2003–2008
by Persell, Stephen D
Hypertension (Dallas, Tex. 1979), 2011, Vol.57 (6), p.1076-1080
5.
Randomized Comparison of Renal Denervation Versus Intensified Pharmacotherapy Including Spironolactone in True-Resistant Hypertension: Six-Month Results From the Prague-15 Study
by Rosa, Ján
Hypertension (Dallas, Tex. 1979), 2015, Vol.65 (2), p.407-413
6.
Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data
by Sundström, Johan
The Lancet (British edition), 2014, Vol.384 (9943), p.591-598
7.
Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Health System
by Chang, Alex R
Hypertension (Dallas, Tex. 1979), 2016, Vol.67 (6), p.1181-1188
8.
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis
by Xie, Xinfang, MD
The Lancet (British edition), 2016, Vol.387 (10017), p.435-443
9.
Catheter-Based Renal Nerve Ablation and Centrally Generated Sympathetic Activity in Difficult-to-Control Hypertensive Patients: Prospective Case Series
by Brinkmann, J
Hypertension (Dallas, Tex. 1979), 2012, Vol.60 (6), p.1485-1490
10.
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial
by Sandset, Else Charlotte, MD
The Lancet (British edition), 2011, Vol.377 (9767), p.741-750
11.
Reexamining the Effect of Antihypertensive Medications on Falls in Old Age
by Lipsitz, Lewis A
Hypertension (Dallas, Tex. 1979), 2015, Vol.66 (1), p.183-189
12.
High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis
by Tomaszewski, Maciej
Heart (British Cardiac Society), 2014, Vol.100 (11), p.855-861
13.
Structure-Based Identification of Small-Molecule Angiotensin-Converting Enzyme 2 Activators as Novel Antihypertensive Agents
by Hernández Prada, José A
Hypertension (Dallas, Tex. 1979), 2008, Vol.51 (5), p.1312-1317
14.
Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial
by Garway-Heath, David F, Prof
The Lancet (British edition), 2015, Vol.385 (9975), p.1295-1304
15.
Association of Hypertension Drug Target Genes With Blood Pressure and Hypertension in 86 588 Individuals
by Johnson, AD
Hypertension (Dallas, Tex. 1979), 2011, Vol.57 (5), p.903-U99
16.
Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension
by Chapman, Neil
Hypertension (Dallas, Tex. 1979), 2007, Vol.49 (4), p.839-845
17.
Chlorthalidone Compared With Hydrochlorothiazide in Reducing Cardiovascular Events: Systematic Review and Network Meta-Analyses
by Roush, George C
Hypertension (Dallas, Tex. 1979), 2012, Vol.59 (6), p.1110-1117
18.
Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis
by Webb, Alastair JS, BMBCh
The Lancet (British edition), 2010, Vol.375 (9718), p.906-915
19.
The CHIPS Randomized Controlled Trial (Control of Hypertension in Pregnancy Study): Is Severe Hypertension Just an Elevated Blood Pressure?
by Magee, Laura A
Hypertension (Dallas, Tex. 1979), 2016, Vol.68 (5), p.1153-1159
20.
Aliskiren, an Orally Effective Renin Inhibitor, Provides Antihypertensive Efficacy Alone and in Combination With Valsartan
by Pool, James L
American journal of hypertension, 2007, Vol.20 (1), p.11-20
